The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 41.50
Bid: 40.00
Ask: 43.00
Change: 0.00 (0.00%)
Spread: 3.00 (7.50%)
Open: 41.50
High: 41.50
Low: 41.50
Prev. Close: 41.50
FIPP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Nandi Proteins Ltd: Further Successful Fundraising

7 Mar 2016 07:00

RNS Number : 1514R
Frontier IP Group plc
07 March 2016
 

 

AIM: FIPP

7 March 2016

 

Frontier IP Group Plc

("Frontier IP" or the "Group")

 

Nandi Proteins Limited - Further Successful Fundraising

 

Frontier IP, which specialises in the commercialisation of intellectual property, is pleased to announce that the latest funding round for its portfolio company Nandi Proteins Limited ("Nandi") has been achieved, at a valuation of £7.57 million, at twice the price per share of the previous fundraising in November 2014.

 

Nandi has raised £250,000 from new and existing investors, which will result in Frontier IP's holding in Nandi being revalued upwards by £0.78 million. The increase will be recognised in the Group's forthcoming half-year results for the period ended 31 December 2015. Frontier IP retains a 20.8% holding in the issued share capital of Nandi.

 

Nandi, which spun out from Heriot-Watt University, Edinburgh, is commercialising a patented protein process technology which can reduce sugars, fats and emulsifiers in processed food without adversely impacting taste and texture. Nandi's technology is being rolled out at a time when food companies are under increasing legislative pressure to reduce the level of these ingredients in their products. Nandi's technology enables food industry customers to remain competitive in response to healthier eating trends using sustainable, naturally-occurring proteins in food manufacture.

 

This funding will enable Nandi to develop further its relationships with multinational food companies, where strong interest has already been shown, extend its product range and prepare for scale-up.

 

Dr. Lydia Campbell, Chief Technology Officer of Nandi, said:

 

"Frontier IP has been instrumental in successfully securing this fundraising which will leverage our relationships in the food sector at a time when the industry is seeking effective ways to address consumer health. The potential of Nandi's technology to address the health of consumers is increasingly recognised by major food companies and we are now investing to commercialise our technology to address this demand."

 

Neil Crabb, Chief Executive of Frontier IP, said:

 

"Nandi's technology enables food companies to improve the nutritional profile of their products. Frontier IP has been delighted to assist with Nandi's funding round and will continue to deploy its resources to support the rapid commercialisation of this timely technology which offers a solution to such an urgent requirement for the food industry."

 

 

Enquiries

 

Frontier IP Group Plc

T: 0131 240 1251

Neil Crabb, Chief Executive

Cantor Fitzgerald Europe

(Nominated Adviser and Joint Broker)

T: 020 7894 7000

David Foreman, Catherine Leftley, Corporate Finance

David Banks, Corporate Broking

Peterhouse Corporate Finance Limited

(Joint Broker)

T: 020 7469 0935

Lucy Williams

Kreab

(Financial PR)

T: 020 7074 1800

Robert Speed, Matthew Jervois

 

 

Notes to Editor:

 

About Frontier IP Group plc

www.frontierip.co.uk.

Frontier IP specialises in assisting institutions and companies in the commercialisation and exploitation of their intellectual property. It establishes formal and informal relationships with sources of exploitable IP, principally universities. Its core business is building and growing a portfolio of equity stakes in spin-out companies by taking an active involvement in the commercialisation and funding of these businesses.

 

About Nandi Proteins Limited

Nandi exploits its patented technology and know-how to improve the functionality of protein-based food ingredients. The structural change in proteins during heat treatment is manipulated to add value to common naturally occurring proteins, which have a wide range of applications in the food industry. Nandi's products are particularly effective as sugar, fat and emulsifier replacers enabling lower fat, lower sugar and clean-label product.

 

Dr. Lydia Campbell, Chief Technology Officer of Nandi, has led the development of Nandi's breakthrough technology. She holds a PhD in Biochemistry from the University of Witwatersrand, South Africa and has completed a post-doctoral study in protein chemistry. Lydia has extensive R&D and product application experience gained during 9 years with Nestle Switzerland, Germany and South Africa.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCMMGGFKDRGVZM
Date   Source Headline
29th Jul 20209:11 amRNSHolding(s) in Company
28th Jul 20205:22 pmRNSHolding(s) in Company
22nd Jul 202012:50 pmRNSHolding(s) in Company
21st Jul 20209:05 amRNSSecond Price Monitoring Extn
21st Jul 20209:00 amRNSPrice Monitoring Extension
21st Jul 20207:00 amRNSResult of Capital Raising
20th Jul 20204:37 pmRNSPrimaryBid.com Offer
20th Jul 20204:35 pmRNSProposed Capital Raising of a minimum of £2m
20th Jul 20202:00 pmRNSCambridge Raman Imaging completes £250,000 funding
14th Jul 20207:00 amRNSAquaInSilico wins grant to commercialise software
13th Jul 20207:00 amRNSPulsiv demonstrates strong progress
7th Jul 20207:00 amRNSCelerum supports development for PlanSea Solutions
6th Jul 20207:00 amRNSBosch collaboration with Fieldwork
30th Jun 20205:00 pmRNSTotal Voting Rights
23rd Jun 20207:00 amRNSThe Vaccine Group: strong COVID-19 progress
17th Jun 20207:00 amRNSCambridge & FIPP collaborate to tackle gum disease
28th May 20207:10 amRNSPortfolio news: Access to Elute's Patent Reader
28th May 20207:00 amRNSExercise of Options and Total Voting Rights
26th May 20207:00 amRNSPortfolio news – Exscientia raises $60 million
7th May 20207:00 amRNSExscientia and SRI International collaborate
1st May 20207:00 amRNSPortfolio news – Molendotech raises £425,000
15th Apr 20207:00 amRNSPortfolio news – Pulsiv Solar awarded patent
9th Apr 20207:00 amRNSPortfolio news: Alusid launches luxury Block range
6th Apr 202012:01 pmRNSHolding(s) in Company
1st Apr 20207:00 amRNSExscientia announces joint initiative re COVID-19
30th Mar 20204:40 pmRNSSecond Price Monitoring Extn
30th Mar 20204:36 pmRNSPrice Monitoring Extension
30th Mar 20207:00 amRNSElute Intelligence’s AI to back COVID-19 research
26th Mar 20207:00 amRNSPortfolio news: new portfolio company AquaInSilico
25th Mar 20207:00 amRNSUnaudited Half Year Results
19th Mar 20207:00 amRNSFrontier partners University of Lisbon competition
17th Mar 20203:15 pmRNSNotice of interim results
13th Mar 20207:00 amRNSPortfolio news – The Vaccine Group Update
12th Mar 202011:05 amRNSSecond Price Monitoring Extn
12th Mar 202011:00 amRNSPrice Monitoring Extension
19th Feb 202012:37 pmRNSHolding(s) in Company
17th Feb 20207:00 amRNSCRIL wins EUR140,000 EU Graphene Flagship funding
12th Feb 20207:00 amRNSPortfolio news - FIPP increases stake in Celerum
31st Jan 20207:00 amRNSPortfolio news - Exscientia
20th Jan 20207:00 amRNSPortfolio news - The Vaccine Group raises £680,000
16th Jan 20203:28 pmRNSHolding(s) in Company
14th Jan 20207:00 amRNSFieldwork Robotics secures first equity funding
10th Jan 20207:00 amRNSExscientia enters collaboration with Bayer AG
31st Dec 20191:00 pmRNSTotal Voting Rights
16th Dec 201910:36 amRNSExercise of Options and Issue of Equity
11th Dec 20196:03 pmRNSHolding(s) in Company
9th Dec 20193:25 pmRNSHolding(s) in Company
9th Dec 20193:21 pmRNSHolding(s) in Company
9th Dec 20192:08 pmRNSHolding(s) in Company
9th Dec 20199:46 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.